CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss

Fraser L. Collins, Jessica O. Williams, Anja C. Bloom, Ravinder K. Singh, Lauren Jordan, Michael D. Stone, Laura R. McCabe, Eddie C.Y. Wang, Anwen S. Williams* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)
4 Downloads (Pure)


Reduced bone density and secondary osteoporosis, resulting in increased risk of fracture, is a significant complicating factor in the inflammatory arthritides. While the exact etiology of systemic bone loss is not fully elucidated, recent insights into the tumor necrosis factor super family (TNFSF) revealed a potential role for death receptor 3 (DR3/TNFRSF25) and one of its ligands, TNF-like protein 1A (TL1A/TNFSF15). The mechanisms by which DR3/TL1A signalling modulates bone loss are unclear. We investigated the effect of DR3/TL1A signalling upon osteoclast-dependent chemokine and MMP production to unravel novel mechanisms whereby this pathway regulates OC formation and OC-dependent bone resorption. Collagen induced arthritis (CIA) was established in DR3wt and DR3ko mice, joints were sectioned and analysed histologically for bone damage while systemic trabecular bone loss distal to the affected joints was compared by micro-CT. Ablation of DR3 protected DBA/1 mice against the development and progression of CIA. In DR3ko, joints of the ankle and mid-foot were almost free of bone erosions and long bones of mice with CIA were protected against systemic trabecular bone loss. In vitro, expression of DR3 was confirmed on primary human CD14+ osteoclast precursors by flow cytometry. These cells were treated with TL1A in osteoclast differentiation medium and TRAP+ osteoclasts, bone resorption, levels of osteoclast-associated chemokines (CCL3, CCL2 and CXCL8) and MMP-9 measured. TL1A intensified human osteoclast differentiation and bone resorption and increased osteoclast-associated production of CCL3 and MMP-9. Our data reveals the DR3 pathway as an attractive therapeutic target to combat adverse bone pathology associated with inflammatory arthritis. We demonstrate that DR3 is critical in the pathogenesis of murine CIA and associated secondary osteoporosis. Furthermore, we identify a novel mechanism by which the DR3/TL1A pathway directly enhances human OC formation and resorptive activity, controlling expression and activation of CCL3 and MMP-9.
Original languageEnglish
Pages (from-to)94-104
Number of pages11
Early online date4 Jan 2017
Publication statusPublished - Apr 2017
Externally publishedYes

Bibliographical note

FLC was funded by an Arthritis Research UK PhD studentship (Grant
code: 18598) awarded to ASW, ECYW and MDS. JOW was funded by a
British Heart Foundation PhD studentship (Reference: FS/11/26/
28750). ACB's PhD studentship was jointly funded by the School of
Medicine and Rheumatology Research Fund (Cardiff University) and LJ's
PhD studentship was jointly funded by the School of Medicine and the
President's Scholarship Fund (Cardiff University) awarded to ASW.
ECYW was additionally funded by MRC Project Grant G0901119.


  • CCL3
  • Collagen-induced arthritis
  • MMP-9
  • Osteoclast
  • Osteoporosis
  • TNFRSF25
  • TNFSF15


Dive into the research topics of 'CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss'. Together they form a unique fingerprint.

Cite this